Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Respiratory Medicine Thoracic Tumor

Thoracic Tumor

Advances in therapeutic strategies for NSCLC

  • Open Access
  • NSCLC
  • Review

The changing landscape of NSCLC treatment provides numerous novel options, but how can they best be incorporated into clinical practice to improve patient outcomes?

Read more

Editor's Choice

Radiation-induced lung injury

What are the underlying mechanisms that cause radiation-induced lung injury, the most common adverse effect of thoracic radiotherapy? What is the prognosis and how can it be treated?

Advances in targeting MET in NSCLC

  • Open Access
  • NSCLC
  • Review

MET exon 14 skipping mutations occur in 3–4% of patients with NSCLC and are associated with poor response to chemotherapy. MET inhibitors have shown great promise – learn about these and other agents being investigated.

Synchronous breast cancer and pleural mesothelioma

A woman who underwent mastectomy and chemotherapy for breast cancer subsequently developed chest pain and dyspnea. Would you have considered pleural mesothelioma as the cause?

Biomarkers of response to immunotherapy in SCLC

Traditional biomarkers are not useful for guiding immunotherapeutic decision-making in small-cell lung cancer. So what biomarkers could help? Explore the evidence from preclinical and clinical studies.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Register today

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares
Listen now
Podcast

Latest News

Toripalimab addition boosts extensive-stage SCLC survival

  • 22-11-2024
  • SCLC
  • News

Quitting smoking early after cancer diagnosis improves survival

Overcoming resistance to PD-(L)1 inhibitors in NSCLC

Novel agent shows promise in MTAP-deleted solid tumors

AI model can predict tumor mutations

High corticosteroid peak doses adversely affect ICI efficacy

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Case Studies

Synchronous breast cancer and pleural mesothelioma

A woman who underwent mastectomy and chemotherapy for breast cancer subsequently developed chest pain and dyspnea. Would you have considered pleural mesothelioma as the cause?

Late-onset ICI-related pneumonitis

Pneumonitis related to ICI therapy typically occurs within the first few months of treatment, but this lung cancer patient experienced the adverse event 2.5 months after discontinuing pembrolizumab, underscoring the need for long-term vigilance.

Tracheopericardial fistula masquerading as acute MI

Tracheopericardial fistula is often misdiagnosed due to its rarity and nonspecific presentation. In this patient with recurrent lung cancer, it was initially mistaken for an acute myocardial infarction.

Current Reviews

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy …

Best of ESMO: pan-tumor highlights

  • Open Access
  • NSCLC
  • short review

During the European Society for Medical Oncology (ESMO) 2024 scientific meeting, multiple groundbreaking trials from organ-specific studies were reported. Additionally, results from early clinical trials in the tumor-agnostic space, such as the …

Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution

The development of antibody–drug conjugates (ADCs) from concept to clinical use reflects the significant progress in cancer treatment. Inspired by Paul Ehrlich's early 20th-century notion of "magic bullets"—agents designed to target …

Pros and cons of reporting incidental findings in lung cancer screening

Based on the evidence of a significant reduction in lung cancer (LC)-related mortality in high-risk individuals [ 1 , 2 ], low-dose Computed Tomography (LDCT) lung cancer screening (LCS) is increasingly endorsed by national stakeholders and …

CME & eLearning

Webinar

In this interactive webinar, experts discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations. 

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Developed by: Springer Healthcare

eLearning | Interviews | Digital Treatment Map | Patient Cases (Link opens in a new window)

0.75 AMA PRA Category 1 Credit(s)™

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)™

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

Further Reading

Lung lesion detectability on images obtained from decimated and CNN-based denoised [18F]-FDG PET/CT scan: an observer-based study for lung-cancer screening

Lung cancer is the leading cause of death in oncological patients with estimated 380′000 death cases in Europe during the year 2020 [ 1 ]. In addition to eliminating the main risk factor (tobacco use), early diagnosis of lung cancer is proven …

Prognostic Benefit of Segmentectomy for Patients with Low Muscle Mass in Early-Stage Lung Cancer

  • Open Access
  • Sarcopenia
  • Thoracic Oncology and Esophageal Cancer

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook

Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy …

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada

  • Open Access
  • Alectinib
  • Original Research Article

Lung cancer is the most commonly diagnosed cancer and most frequent cause of cancer-related death worldwide, with around 2.5 million cases and 1.8 million deaths reported in 2022 [ 1 , 2 ]. In Canada, for example, an estimated 31,000 new lung …

Related topics

Advances in therapeutic strategies for NSCLC

  • Open Access
  • NSCLC
  • Review

The changing landscape of NSCLC treatment provides numerous novel options, but how can they best be incorporated into clinical practice to improve patient outcomes?

Read more

Advances in targeting MET in NSCLC

  • Open Access
  • NSCLC
  • Review

Biomarkers of response to immunotherapy in SCLC

ICIs in lung cancer: the impact of concomitant medications

Late-onset ICI-related pneumonitis

Emerging therapies for brain metastases

Image Credits